According to Zhitong Financial App, Viva Biotech (01873.HK) announced that Arthrosi Therapeutics will meet the company. On December 13, 2025, the buyer Sobi US Holding Corp. has agreed to acquire Arthrosi Therapeutics through a merger and acquisition. Following completion, the Company will no longer hold any shares in Arthrosi Therapeutics. The merger and acquisition agreement stipulates an advance payment of $950 million (subject to customary adjustments) and possibly no more than $550 million to be paid upon completion.

According to Zhitong Financial App, Viva Biotech (01873.HK) announced that Arthrosi Therapeutics will meet the company. On December 13, 2025, the buyer Sobi US Holding Corp. has agreed to acquire Arthrosi Therapeutics through a merger and acquisition. Following completion, the Company will no longer hold any shares in Arthrosi Therapeutics. The merger and acquisition agreement stipulates an advance payment of $950 million (subject to customary adjustments) and possibly no more than $550 million to be paid upon completion.